Promoter Methylation of ER Gene and Clinicopathologic Features in Hepatocellular Carcinoma

ZHANG Chang-song,LI Ke,LI Zheng-you,JIA Feng-qi,LI Rong,WU Meng-chao,WEI Li-xin
DOI: https://doi.org/10.3969/j.issn.1673-5269.2007.04.002
2007-01-01
Abstract:OBJECTIVE:To investigate the relationship between promoter of ER methylation and ER mRNA expression and clinicopathologic features in hepatocellular carcinoma (HCC). And to observe the effects of 5-aza-2-deoxycytidine (5-aza-dc) in regulating ER mRNA expression. METHODS: Promoter methylation of the ER gene was determined by methylation-specific PCR (MSP) in HCC and non-tumor cases. And the expression of ER mRNA was investigated by RT-PCR. Two hepatic cancer cell lines SMMC-7721 and HepG2 were treated with DNA methyltransferase inhibitor, 5-aza-dc. RESULTS: Promoter of the ER gene was methylated in 60.0%(18/30)of HCC and 30.0%(9/30)of non-tumor tissues,respectively. Statistically significant association was found between the status of aberrant methylation in HCC and non-tumor case, χ2=5.455,P=0.037. The expression of ER mRNA was 40.0% (12/30) in HCC, while the expression of ER mRNA was 22.2% and 66.7% in methylated HCC cases and unmethylated HCC cases, respectively. An inverse correlation was found between promoter methylation and ER mRNA transcript levels in HCC, χ2=5.93,P=0.024. Meanwhile, there was a significant association between methylation of the ER gene and serum AFP level, χ2=12.13,P=0.001. The study shows that low micromolar concentrations of 5-aza-dc induce the ER mRNA expression of in HCC cancer lines. CONCLUSION: Promoter methylation of ER gene is a frequent event in HCC and may contribute to pathogenesis of HCC through silencing ER mRNA expression.
What problem does this paper attempt to address?